六价疫苗头对头研究:我们可以学到什么?
该系统综述检索多个电子数据库,纳入12篇已发表的六价疫苗头对头比较研究。三种欧美获批六价疫苗安全性均可接受,但反应原性存在差异;两种较新疫苗免疫原性非劣效于DT3aP-HBV-IPV/Hib,但常见抗原免疫应答差异的临床相关性未确立。2+1接种程序免疫应答略低,仅建议在接种覆盖率极高的国家考虑。
要点
- 三种六价疫苗安全性均可接受,但反应原性存在显著差异。
- 较新疫苗免疫原性非劣效于DT3aP-HBV-IPV/Hib,但部分抗原应答差异临床意义未明。
- 2+1程序免疫应答略低于3+1,仅建议高接种覆盖率国家考虑。
核心结论
- 已获批六价疫苗总体相似,但头对头免疫原性数据提示差异可能与组成和配方不同有关。
- 较新疫苗对DT3aP-HBV-IPV/Hib的免疫原性非劣效性不足以完全桥接相似的效力、效果和安全性。
- DT3aP-HBV-IPV/Hib已有超过20年使用经验,积累了大量长期免疫原性、安全性和有效性数据。
研究设计与样本
- 系统文献检索多个电子数据库,纳入已发表的同行评议头对头研究,比较任何已获批六价疫苗与另一种六价疫苗。
- 共12篇文章符合预设纳入标准。
主要发现
- 个别研究结论认为三种六价疫苗安全性均可接受,但反应原性特征观察到一些显著差异。
- DT2aP-HBV-IPV-Hib和DT5aP-HBV-IPV-Hib的免疫原性非劣效于DT3aP-HBV-IPV/Hib。
- 常见抗原免疫应答存在一些差异,但其临床相关性未确立。
- 与DT3aP-HBV-IPV/Hib受种者相比,DT2aP-HBV-IPV-Hib受种者抗百日咳丝状血凝素(FHA)和抗Hib多聚核糖基核糖醇磷酸(PRP)抗体浓度倾向更高,抗HBV和抗百日咳毒素(PT)抗体浓度倾向更低。
- 与DT3aP-HBV-IPV/Hib受种者相比,DT5aP-HBV-IPV-Hib受种者抗PT和基础免疫后抗PRP抗体浓度倾向更高,抗HBV、抗FHA、抗百日咳pertactin及加强免疫后抗PRP抗体浓度倾向更低。
关键数值与推荐
- 2+1接种程序仅应在接种覆盖率极高的国家考虑。
临床怎么用
- 选择六价疫苗时可参考头对头免疫原性差异,但需注意部分差异临床相关性未确立。
- 在接种覆盖率极高的国家可考虑2+1程序,但需权衡其免疫应答略低于3+1程序。
- DT3aP-HBV-IPV/Hib具有超过20年长期免疫原性、安全性和有效性数据,可作为儿童免疫规划的关键支柱。
局限性
- 免疫原性非劣效性不能完全桥接相似的效力、效果和安全性。
- 常见抗原免疫应答差异的临床相关性未确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Three hexavalent vaccines against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B virus (HBV), and Haemophilus influenzae type b (Hib) are licensed in Europe: Infanrix hexa (DT3aP-HBV-IPV/Hib), Hexyon (DT2aP-HBV-IPV-Hib) and Vaxelis (DT5aP-HBV-IPV-Hib). METHODS: A systematic literature search was performed in various electronic databases to identify published peer-reviewed head-to-head studies comparing any licensed hexavalent vaccine to another. RESULTS: Predefined inclusion criteria were met by 12 articles. Individual studies concluded that the 3 hexavalent vaccines have acceptable safety profiles although some significant differences were observed in their reactogenicity profiles. The immunogenicity of DT2aP-HBV-IPV-Hib and DT5aP-HBV-IPV-Hib was non-inferior versus DT3aP-HBV-IPV/Hib. Some differences in immune responses to common antigens were observed, but their clinical relevance was not established. Anti-filamentous hemagglutinin (FHA) from pertussis and anti-polyribosylribitol phosphate (PRP) from Hib antibody concentrations tended to be higher, and anti-HBV and anti-pertussis toxin (PT) from pertussis antibody concentrations lower in DT2aP-HBV-IPV-Hib versus DT3aP-HBV-IPV/Hib vaccinees. Anti-PT and post-primary anti-PRP antibody concentrations tended to be higher, and anti-HBV, anti-FHA, anti-pertactin from pertussis and post-booster anti-PRP antibody concentrations lower in DT5aP-HBV-IPV-Hib versus DT3aP-HBV-IPV/Hib recipients. Slightly lower immune responses towards most vaccine antigens were observed with 2 + 1 versus 3 + 1 schedules post-primary vaccination, suggesting that 2 + 1 schedules should only be considered in countries with very high vaccination coverage. CONCLUSION: Although the licensed hexavalent vaccines are generally considered similar, analyses of immunogenicity data from head-to-head trials highlighted differences that could be related to differences in composition and formulation. In addition, the demonstrated non-inferiority of the immunogenicity of the more recent vaccines versus DT3aP-HBV-IPV/Hib does not allow a full bridging to similar efficacy, effectiveness and safety. The availability of DT3aP-HBV-IPV/Hib over > 20 years allowed to collect a wealth of data on its long-term immunogenicity, safety and effectiveness in clinical and post-marketing studies, and makes it a key pillar of pediatric immunization.
引用
- Knuf M, Haas H, Garcia-Corbeira P, et al. Hexavalent vaccines: What can we learn from head-to-head studies? Vaccine. 2021. PMID: 34531081. doi:10.1016/j.vaccine.2021.08.086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。